Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback